Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 12

Magnesium Sulfate Improves Some Risk Factors for Atherosclerosis in Patients Suffering from One or Two Coronary Artery Diseases: A Double-blind Clinical Trial Study

Authors Sobhani AR, Farshidi H, Azarkish F, Eslami M, Eftekhar E, Keshavarz M, Soltani N

Received 12 May 2020

Accepted for publication 7 August 2020

Published 25 September 2020 Volume 2020:12 Pages 159—169

DOI https://doi.org/10.2147/CPAA.S261264

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Arthur Frankel


Ali Reza Sobhani,1 Hossein Farshidi,2 Fariba Azarkish,3 Mahdiya Eslami,2 Ebrahim Eftekhar,4 Mansoor Keshavarz,5 Nepton Soltani6

1Clinical Pathology Department, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 2Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 3Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 4Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; 5Physiology Department, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 6Physiology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence: Nepton Soltani
Physiology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Tel +98 9133251067
Fax +98 36688597
Email neptun.soltani@med.mui.ac.ir

Purpose: Given the beneficial effect of MgSO4 on the cardiovascular system, this study was designed to investigate the effect of MgSO4 administration on suppressing some atherosclerotic risk factors in moderate coronary artery disease patients with one or two atherosclerotic vessels.
Patients and Methods: In a randomized double-blind placebo-controlled clinical trial study, 64 patients with moderate coronary artery disease (55– 69% stenosis) were selected according to angiography findings. Patients were divided into four groups including patients with one or two atherosclerotic vessels treated with MgSO4 (Mg-treated-VR1, Mg-treated-VR2, respectively), placebo treated patients with one or two atherosclerotic vessels (Control-VR1, Control-VR2, respectively). The patients received either placebo or MgSO4 supplement capsule containing 300 mg MgSO4 for six months on a daily basis. ESR, Ca/Mg ratio, urine Mg level, serum Mg, fibrinogen, homocysteine, uric acid, Na, K, Ca, CRP, T3, T4, TSH, BUN, and Cr concentrations were measured at baseline and every three months.
Results: Serum T3, Ca, K, homocysteine, CRP, and Mg concentrations were significantly improved in Mg-treated groups compared to placebo groups.
Conclusion: The results of this study showed that despite the slight change in serum magnesium level, oral administration of MgSO4for six months could slightly reduce the serum levels of some inflammatory and vascular factors in moderate coronary artery disease patients.

Keywords: atherosclerosis, MgSO4, fibrinogen, CRP, homocysteine, thyroid hormones

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]